Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke.

Schneider, D; Berrouschot, J; Brandt, T; Hacke, W; Ferbert, A; Norris, S H; Polmar, S H; Schäfer, E

Schneider, D; Berrouschot, J; Brandt, T; Hacke, W; Ferbert, A; Norris, S H; Polmar, S H; Schäfer, E.

Affiliation

Schneider D; Department of Neurology, University of Leipzig, Leipzig, Germany.

Eur Neurol ; 40(2): 78-83, 1998 Aug.

Article in En | MEDLINE | ID: mdl-9693236

Subject(s)

Antibodies, Monoclonal/pharmacokinetics; Antibodies, Monoclonal/therapeutic use; Brain Ischemia/drug therapy; Cerebral Hemorrhage/drug therapy; Acute Disease; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal/blood; Binding Sites; Brain Ischemia/rehabilitation; Cerebral Hemorrhage/rehabilitation; Dose-Response Relationship, Drug; Drug Labeling; Enzyme-Linked Immunosorbent Assay; Female; Hospitalization; Humans; Intercellular Adhesion Molecule-1/metabolism; Male; Middle Aged; Prospective Studies; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Cerebral Hemorrhage / Brain Ischemia / Antibodies, Monoclonal Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur Neurol Year: 1998 Document type: Article Affiliation country: Germany Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links